Vaccines New

In early September 2021, the Delta variant is the dominant SARS-CoV-2 strain in most countries. Unless otherwise stated, all information refers to COVID-19 vaccines in the context of infection with and transmission of the Delta variant.


Gliederung am Anfang

Vaccines – Efficacy – Adverse events – Special populations – Special Topics

As of 1 September 2021, four COVID-19 vaccines have been approved or authorized for emergency use in the EU or the US:

  • The BioNTech/Pfizer vaccine. Trade name: Comirnaty™ (tozinameran, formerly known as BNT162b2)
  • The Moderna vaccine, also known as mRNA-1273
  • The AstraZeneca/University of Oxford vaccine. Trade name: Vaxzevria™/Covishield™ (formerly known as ChAdOx1 nCoV-19, AZD1222)
  • The Johnson & Johnson (Janssen) vaccine, also known as Ad26.COV2.S

Outside the EU and the US, other vaccines have been approved, for example:

  • BBIBP-CorV, Sinopharm and the Beijing Institute of Biological Products – first approved in China on 30 December 2020
  • Covaxin, Bharat Biotech – first approved in India on 3 January 2021
  • Sputnik-V, Gamaleya Research Institute – first approved in Russia, 28 December 2020
  • Convidecia, CanSinoBIO – first approved in China, 25 February 2021


  • BioNTech-Pfizer
  • Moderna
  • AstraZeneca
  • Johnson & Johnson
  • Sputnik


Correlates of protection

Duration of immune response

Breakthrough infections and Transmissibility

Booster Dose

Two shots, two vaccines

One vaccine dose after previous SARS-CoV-2 infection

Vaccines_Adverse Events




Facial paralysis

Vaccines_Special populations

Older people

Pregnant women






Chronic lymphocytic leukemia (CLL)

Multiple myeloma

Solid Organ Transplant





Vaccines_Special topics

Post-exposure SARS-CoV-2 vaccination

Delayed booster injection


Protection of the non-vaccinated